Authors: S Kunzmann W Thomas B Mayer S Kuhn H Hebestreit
Publish Date: 2010/03/05
Volume: 38, Issue: 2, Pages: 131-134
Abstract
We report a 23yearold female patient with cystic fibrosis developing severe intravascular hemolysis with a minimal hemoglobin level of 16 g/dl after 7 days of treatment with piperacillin consistent with an immunemediated hemolytic crisis Twenty days later the patient could leave the hospital in good condition without any neurological deficit To our knowledge this is the lowest reported hemoglobin value caused by hemolytic anemia with intact survival As piperacillin is commonly used in patients with cystic fibrosis it is important to monitor the fullblood counts of patients during treatment with piperacillin and to be aware of the potential for hemolytic anemia to develop Antipiperacillin antibodies should be considered whenever these patients develop hemolytic anemia or a positive direct antiglobulin test DAT Furthermore drugfever under piperacillin application could be a warning sign for the development of hemolytic anemia
Keywords: